Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03433677 · ClinicalTrials.gov registry record · Phase 3
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
A Phase 3 study of Diabetes Type 1, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
- 5
- Study locations
NCT03433677 is a Phase 3 study of Diabetes Type 1 that has completed, run by Eli Lilly and Company. The registered enrollment target is 49 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT03433677, a Phase 3 study of Diabetes Type 1, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes.
Conditions Studied
Interventions
- DRUG Insulin lispro
- DRUG LY900014
Study Locations (5)
Other
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Seville
- For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. - Seville
California
- Valley Research - Fresno
Colorado
- Barbara Davis Center for Childhood Diabetes - Aurora
Georgia
- Atlanta Diabetes Associates - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-02-21 |
| Est. Completion | 2018-09-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03433677
The ClinicalTrials.gov registry entry for NCT03433677 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Type 1 appearing as the primary indexed condition, and to 2 interventions - of which Insulin lispro is the first listed.
NCT03433677 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT03433677 about?
NCT03433677 is a clinical study titled "A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes". The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes.
What is the current status of trial NCT03433677?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2018-02-21. Estimated completion is 2018-09-04.
What conditions does trial NCT03433677 study?
This clinical trial studies the following conditions: Diabetes Type 1.
What interventions are being tested in trial NCT03433677?
The interventions under investigation include: Insulin lispro (DRUG), LY900014 (DRUG).
Who is sponsoring clinical trial NCT03433677?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03433677 being conducted?
This trial has 5 study locations across California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.